- Home
- ANAB vs HSII Comparison
ANAB vs HSII Comparison
Compare ANAB & HSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- HSII
- Stock Information
- Founded
- ANAB 2005
- HSII 1953
- Country
- ANAB United States
- HSII United States
- Employees
- ANAB N/A
- HSII N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- HSII Diversified Commercial Services
- Sector
- ANAB Health Care
- HSII Consumer Discretionary
- Exchange
- ANAB Nasdaq
- HSII Nasdaq
- Market Cap
- ANAB 759.5M
- HSII 904.3M
- IPO Year
- ANAB 2017
- HSII 1999
- Fundamental
- Price
- ANAB $22.23
- HSII $43.66
- Analyst Decision
- ANAB Buy
- HSII Buy
- Analyst Count
- ANAB 10
- HSII 2
- Target Price
- ANAB $42.25
- HSII $48.00
- AVG Volume (30 Days)
- ANAB 559.5K
- HSII 128.1K
- Earning Date
- ANAB 05-05-2025
- HSII 05-05-2025
- Dividend Yield
- ANAB N/A
- HSII 1.37%
- EPS Growth
- ANAB N/A
- HSII N/A
- EPS
- ANAB N/A
- HSII 0.37
- Revenue
- ANAB $111,872,000.00
- HSII $1,116,954,000.00
- Revenue This Year
- ANAB N/A
- HSII $6.05
- Revenue Next Year
- ANAB $9.72
- HSII $1.89
- P/E Ratio
- ANAB N/A
- HSII $118.87
- Revenue Growth
- ANAB 387.20
- HSII 6.10
- 52 Week Low
- ANAB $12.21
- HSII $30.20
- 52 Week High
- ANAB $41.31
- HSII $49.02
- Technical
- Relative Strength Index (RSI)
- ANAB 62.32
- HSII 61.19
- Support Level
- ANAB $20.50
- HSII $40.10
- Resistance Level
- ANAB $22.84
- HSII $44.70
- Average True Range (ATR)
- ANAB 1.28
- HSII 1.27
- MACD
- ANAB 0.12
- HSII 0.08
- Stochastic Oscillator
- ANAB 83.24
- HSII 64.03
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.